Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Increased to Buy (B-) at Weiss Ratings

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by research analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a report on Monday. Finally, UBS Group reiterated a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.9%

Shares of FMS opened at $27.07 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $18.94 and a twelve month high of $30.46. The firm’s 50 day moving average price is $25.26 and its two-hundred day moving average price is $26.18.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. As a group, research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 34.0% in the first quarter. GAMMA Investing LLC now owns 9,603 shares of the company’s stock valued at $239,000 after purchasing an additional 2,439 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 22.4% in the first quarter. Cerity Partners LLC now owns 39,903 shares of the company’s stock valued at $994,000 after purchasing an additional 7,299 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at $164,000. Advisors Asset Management Inc. increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 243.3% in the first quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company’s stock valued at $195,000 after purchasing an additional 5,540 shares during the last quarter. Finally, Kestra Private Wealth Services LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at $286,000. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.